Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Safety and Biodistribution Evaluation in Cynomolgus Macaques of rAAV2tYF-PR1.7-hCNGB3, a Recombinant AAV Vector for Treatment of Achromatopsia

1 Mar 2016

Abstract excerpt

Applied Genetic Technologies Corporation (AGTC) is developing rAAV2tYF-PR1.7-hCNGB3, a recombinant adeno-associated viral (rAAV) vector expressing the human CNGB3 gene, for treatment of achromatopsia, an inherited retinal disorder characterized by markedly reduced visual acuity, extreme light sensitivity, and absence of color discrimination. We report here results of a study evaluating the safety and...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Herpesvirus Infections and Treatments
Share to Mosquito-borne diseases and control
Share to Retinal Development and Disorders

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 27003753
DOI: 10.1089/humc.2015.164

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Safety and Biodistribution Evaluation in Cynomolgus Macaques of rAAV2tYF-PR1.7-hCNGB3, a Recombinant AAV Vector for Treatment of AchromatopsiaPMID 27003753Read ↗

Safety and Efficacy Evaluation of rAAV2tYF-PR1.7-hCNGA3 Vector Delivered by Subretinal Injection in CNGA3 Mutant Achromatopsia SheepSemantic proximity Read ↗

Safety and Biodistribution Evaluation in Cynomolgus Macaques of rAAV2tYF-CB-hRS1, a Recombinant Adeno-Associated Virus Vector Expressing RetinoschisinSemantic proximity Read ↗

Development of Methodology and Study Protocol: Safety and Efficacy of a Single Subretinal Injection of rAAV.hCNGA3 in Patients with CNGA3-Linked Achromatopsia Investigated in an Exploratory Dose-Escalation Trial.Semantic proximity Read ↗

Preclinical Safety Evaluation of AAV5-hRORA Gene Therapy for Geographic Atrophy and ABCA4-Related RetinopathiesSemantic proximity Read ↗

Host immune responses after suprachoroidal delivery of AAV8 in nonhuman primate eyesSemantic proximity Read ↗

Ocular Safety and Toxicology of Subretinal Gene Therapy With rAAV.hPDE6A in Nonhuman PrimatesSemantic proximity Read ↗

Long-term and age-dependent restoration of visual function in a mouse model of CNGB3-associated achromatopsia following gene therapySemantic proximity Read ↗

Gene therapy rescues cone function in congenital achromatopsiaSemantic proximity Read ↗

Evaluation of Dose and Safety of AAV7m8 and AAV8BP2 in the Non-Human Primate RetinaSemantic proximity Read ↗

Results at 2 Years after Gene Therapy for RPE65-Deficient Leber Congenital Amaurosis and Severe Early-Childhood–Onset Retinal DystrophySemantic proximity Read ↗

Suprachoroidal Delivery of Viral and Nonviral Gene Therapy for Retinal DiseasesSemantic proximity Read ↗

Six Years and Counting: Restoration of Photopic Retinal Function and Visual Behavior Following Gene Augmentation Therapy in a Sheep Model of <i>CNGA3</i> AchromatopsiaSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.